Article Text

Download PDFPDF

Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma
  1. Jasmine H Francis1,
  2. Y Pierre Gobin2,
  3. Scott E Brodie3,
  4. Brian P Marr1,
  5. Ira J Dunkel4,
  6. David H Abramson1
  1. 1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  2. 2Service of Interventional Neuroradiology, Weill Cornell Medical College of New York Presbyterian Hospital, New York, New York, USA
  3. 3Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, USA
  4. 4Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  1. Correspondence to Dr David H Abramson, Chief, Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, 70 East 66th Street, New York, NY 10021, USA; abramsod{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have previously reported on bilateral intra-arterial (IA) chemosurgery for bilateral retinoblastoma, or tandem therapy.1 While this allows both eyes to be treated during the same IA session, it also exposes the patient to twice the dose of chemotherapy (typically melphalan and topotecan). Even at the doses used for IA, the systemic levels of melphalan can be dose-limiting (melphalan may induce neutropenia at doses higher than 0.4 mg/kg). To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye.


Three children with bilateral retinoblastoma (all with Reese–Ellsworth group IVa in one eye and 2b in one fellow eye and 5a in two fellow eyes; International Classification, B: …

View Full Text


  • Funding This work was supported by The Fund for Ophthalmic Knowledge and the New York Community Trust.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the Memorial Sloan Kettering Cancer Center.

  • Provenance and peer review Not commissioned; internally peer reviewed.